{"entity":{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","aka":["Beijing Cancer Hospital","Beijing Institute for Cancer Research","北京大学肿瘤医院"],"tldr":"Beijing's dedicated cancer hospital and the leading Chinese centre for gastric cancer trials, where claudin 18.2 CAR-T and PD-1 combinations were first tested in gastric disease.","summary":"Founded in 1976 as the Beijing Institute for Cancer Research, the hospital is Peking University's cancer centre and a nationally designated clinical speciality in gastrointestinal oncology, gastric surgery, lymphoma, melanoma and sarcoma. Lin Shen's GI oncology department has led or co-led the pivotal Chinese trials of PD-1 antibodies in gastric and oesophageal cancer, the first-in-human claudin 18.2 CAR-T study (satricabtagene autoleucel with CARsgen), and early ADC programmes. Jun Guo's melanoma group defined the biology and treatment of acral and mucosal melanoma, which dominate in East Asia. The hospital runs a large phase 1 unit and the Beijing cancer registry.","asOf":"2026-09-09","links":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org"},{"label":"Peking University Health Science Center","url":"https://www.bjmu.edu.cn"}],"tags":[],"related":[],"cancers":["gastric","esophageal","melanoma","colorectal","dlbcl","sarcoma"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t","checkpoint-inhibitor","adc"],"targets":["cldn18-2","pd1","her2"],"drugs":["satricabtagene-autoleucel","disitamab-vedotin"],"companies":["carsgen","remegen"],"institutions":[],"pathways":[],"terms":["csco-guidelines"],"trials":[],"people":["shen-lin","qi-changsong","ziyu-li","yuqin-song","guo-jun"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Beijing","country":"CN","lat":39.939,"lng":116.291,"institutionType":"cancer-center","website":"https://www.bjcancer.org","university":"Peking University","programs":["Gastric and oesophageal cancer","Claudin 18.2 CAR-T","Acral and mucosal melanoma","Lymphoma","Phase 1 unit"]},"route":"/institutions/pku-cancer-hospital/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/"},{"id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/"}],"company":[{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","route":"/companies/carsgen/"},{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/"}],"collection":[{"id":"csco-guidelines","kind":"collection","name":"CSCO guidelines (China)","route":"/collections/csco-guidelines/"}],"person":[{"id":"qi-changsong","kind":"person","name":"Changsong Qi","route":"/people/qi-changsong/"},{"id":"guo-jun","kind":"person","name":"Jun Guo","route":"/people/guo-jun/"},{"id":"shen-lin","kind":"person","name":"Lin Shen","route":"/people/shen-lin/"},{"id":"yuqin-song","kind":"person","name":"Yuqin Song","route":"/people/yuqin-song/"},{"id":"ziyu-li","kind":"person","name":"Ziyu Li","route":"/people/ziyu-li/"}],"trial":[{"id":"nct04581473","kind":"trial","name":"CT041-ST-01","route":"/trials/nct04581473/"}],"paper":[{"id":"paper-ct041-st-01-lancet-2025","kind":"paper","name":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-ct041-st-01-lancet-2025/"}]}}